Veterinary Biologics Market

Zoetis Services LLC (US) and Elanco (US) are the leading players in the Veterinary Biologics Market

The global veterinary biologics market is projected to reach USD 3.69 billion by 2031, up from USD 2.85 billion in 2026, at a CAGR of 5.3%. Market growth is largely driven by the increasing companion animal population and pet ownership, as well as growing concerns about chronic diseases in animals. Increased adoption of pet insurance, high animal healthcare expenditures, and rising awareness initiatives by government and animal welfare organizations are further boosting market growth.

The prominent players in the veterinary biologics market include Zoetis (US), Elanco (US), and Merck & Co., Inc. (US). These players are constantly involved in developing new products and adopting growth strategies such as partnerships and expansions to strengthen their market reach.

To know about the assumptions considered for the study download the pdf brochure

In July 2026, Zoetis Inc. launched Portela® (relfovetmab) in Canada and the European Union member states. The product is a long-acting anti-nerve growth factor (NGF) monoclonal antibody for managing osteoarthritis pain in cats, providing up to three months of pain relief with a single subcutaneous injection. The launch expands Zoetis’ veterinary monoclonal antibody portfolio beyond canine treatments into feline pain management.

In May 2026, Elanco Animal Health Incorporated began the phased US launch of Befrena™ (tirnovetmab), an anti-interleukin-31 (IL-31) monoclonal antibody injection for treating allergic and atopic dermatitis in dogs. Approved by the USDA in December 2025, the product begins controlling itch within 24 hours and offers a dosing interval of six to eight weeks, expanding Elanco’s veterinary biologics portfolio in canine dermatology.

Zoetis (US)

Zoetis discovers, develops, manufactures, and commercializes biologics and medicines for livestock and companion animals. The company operates through three business segments: Companion Animals, Livestock, and Contract Manufacturing & Human Health. Zoetis offers animal dermatology products through both the Companion Animals and Livestock segments. The company operates in 70 countries, and its products are sold in more than 120 countries through its distribution networks. Significant subsidiaries include Alpharma Animal Health Company (US), Fort Dodge Asia Exports, Inc. (US), and Jilin Pfizer Guoyuan Animal Health Co., Ltd. (China).

Elanco (US)

Elanco is a global leader in animal health, dedicated to delivering innovative products and services that prevent and treat diseases in farm animals and pets. With a portfolio of approximately 200 brands, Elanco provides solutions for various species, including dogs and cats under pet health and cattle, poultry, swine, sheep, and aquaculture under farm animal care. The company primarily operates through one business segment but organizes its sales and operations into three major categories: pet health, farm animal, and contract manufacturing. A key innovation area for Elanco is monoclonal antibody (mAb) therapies. In 2023, Elanco launched the world’s first USDA conditionally approved mAb treatment for canine parvovirus. With ongoing investment in mAb R&D and expanded biologics manufacturing capabilities, Elanco is advancing its pipeline of future antibody-based therapies.

Moreover, the company’s presence spans over 90 countries, showcasing its strong presence in the animal health market.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a global leader in healthcare, delivering innovative solutions such as prescription medications, vaccines, biologic therapies, and animal health products. The company operates through two primary divisions: Pharmaceuticals and Animal Health. Through its Animal Health division, Merck offers monoclonal antibody therapies for companion animals. Merck has a presence in more than 140 countries and operates 25 manufacturing facilities across the Americas, Europe, and Asia-Pacific. The company’s robust R&D network includes 16 research centers in the US, Spain, Germany, Norway, South Africa, India, Australia, Singapore, and Japan. For instance, in May 2025, Merck Animal Health expanded its manufacturing and R&D facilities in De Soto, Kansas, with an investment of USD 895 million. This strategic expansion aims to boost production capacity and innovation, particularly to support biologics and vaccine development, including monoclonal antibody therapies.

Market Ranking

The global veterinary biologics market is competitive, with the top players being Zoetis (US), Elanco (US), and Merck & Co., Inc. (US). Competition among the leading players is intense, and most focus on forming partnerships to secure a stable market share. The market is dominated by key players with a strong global footprint and well-established supply and distribution chains in developed regions such as North America and Europe.

Related Reports:

Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kit, Immunoglobulin & Antitoxin), RoA (Subcutaneous, Oral), Application (Infectious Disease, Dermatology, Pain Management, Oncology), Animal Type, End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]

Veterinary Biologics Market Size,  Share & Growth Report
Report Code
MD 9573
RI Published ON
November 2026
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
X
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
ONLINE CHAT
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved